You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IL15

Showing 26 - 50 of 7,384
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Minneapolis (N-803)

Completed
  • Acute Myelogenous Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Jan 4, 2023

NonHodgkin's Lymphoma Refractory Trial in El Segundo (N803, CD19t-haNK suspension, Cyclophosphamide)

Not yet recruiting
  • NonHodgkin's Lymphoma Refractory
  • El Segundo, California
    CSSIFM
Nov 9, 2022

Human Immunodeficiency Virus Trial in New York, Philadelphia (3BNC117-LS, 10-1074-LS, N803)

Not yet recruiting
  • Human Immunodeficiency Virus
  • New York, New York
  • +2 more
Jul 12, 2022

ACUTE LEUKEMIA Trial in Madrid (Donor IL-15 stimulated NK cells infusion)

Completed
  • ACUTE LEUKEMIA
  • Donor IL-15 stimulated NK cells infusion
  • Madrid, Spain
    Hospital General Universitario Gregorio Marañón
Sep 2, 2021

Merkel Cell Carcinoma Trial in United States (Avelumab, N-803, haNK™)

Terminated
  • Merkel Cell Carcinoma
  • Avelumab
  • +2 more
  • San Francisco, California
  • +4 more
Jan 7, 2022

HIV/AIDS Trial in Bangkok (N-803)

Recruiting
  • HIV/AIDS
  • Bangkok, Thailand
    Thai Red Cross AIDS Research Centre
Oct 4, 2021

Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in United States (NKTR-255 at 1.5 µg/kg, NKTR-255

Recruiting
  • Non-Hodgkin Lymphoma
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • NKTR-255 at 1.5 µg/kg
  • +3 more
  • La Jolla, California
  • +26 more
Jan 10, 2023

HIV Trial in United States (PennVax B, IL-12, IL-15)

Completed
  • HIV Infections
  • PennVax B
  • +2 more
  • Birmingham, Alabama
  • +7 more
Oct 13, 2021

Solid Tumor Trial in Minneapolis (HCW9218)

Recruiting
  • Solid Tumor
  • Minneapolis, Minnesota
    Masonic Cancer Center - University of Minnesota
Apr 12, 2022

Primary Hepatocellular Carcinoma Trial (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for

Not yet recruiting
  • Primary Hepatocellular Carcinoma
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
  • camrelizumab for Injection
  • (no location specified)
Nov 13, 2023

Sarcoma Trial in Beijing (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))

Recruiting
  • Sarcoma
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)
  • Beijing, China
    Peking University People's Hospital
Nov 6, 2023

High-risk Leukemias Trial in Spain (NK cells stimulated ex vivo with IL-15, Alloreactive NK cells)

Recruiting
  • High-risk Leukemias
  • NK cells stimulated ex vivo with IL-15
  • Alloreactive NK cells
  • Santiago De Compostela, A Coruña, Spain
  • +9 more
Mar 30, 2022

B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia Trial in Houston (Fludarabine,

Active, not recruiting
  • B-Lymphoid Malignancies
  • +3 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 1, 2022

Metastatic Gastric Cancer Trial in Beijing (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), Nivolumab

Recruiting
  • Metastatic Gastric Cancer
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
  • Nivolumab Injection
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Aug 23, 2023

Locally Advanced/Metastatic Solid Tumors Trial in United States (BJ-001, Pembrolizumab)

Recruiting
  • Locally Advanced/Metastatic Solid Tumors
  • Saint Louis, Missouri
  • +4 more
Jun 5, 2022

Advanced Malignant Solid Tumor Trial in Hangzhou (Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection)

Not yet recruiting
  • Advanced Malignant Solid Tumor
  • Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，Zhejiang University School of Medi
Jul 25, 2022

MDS, Acute Leukemia Trial in Germany (CIK-Cells)

Active, not recruiting
  • Myelodysplastic Syndromes
  • Acute Leukemia
  • Heidelberg, Baden-Württemberg, Germany
  • +4 more
Mar 31, 2022

Hiv, HIV, Immune Deficiency Trial in Minneapolis (Haploidentical Natural Killer (NK) Cells)

Completed
  • Hiv
  • +2 more
  • Haploidentical Natural Killer (NK) Cells
  • Minneapolis, Minnesota
    University of Minnesota
Apr 21, 2021

Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma Trial

Recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • +10 more
  • Antineoplastic Immune Cell
  • +4 more
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Aug 12, 2022

Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (hCD19.IL15.CAR-iNKT)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • Xuzhou, Jiangsu, China
    The Affiliated hospital of Xuzhou medical University
Mar 24, 2021

COVID-19 Trial in Chongqing (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)

Recruiting
  • COVID-19
  • NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
  • Chongqing, China
    Chongqing Public Health Medical Center
Nov 16, 2020

Advanced Pancreatic Cancer Trial in Hangzhou (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in

Recruiting
  • Advanced Pancreatic Cancer
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab
  • Hangzhou, Zhejiang, China
    the First Affiliated Hospital, School of Medicine, Zhejiang Univ
Mar 8, 2022

Primary Liver Cancer Trial in Hangzhou (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)))

Recruiting
  • Primary Liver Cancer
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Apr 21, 2021

Advanced Malignant Solid Tumor Trial in ShangHai (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)))

Recruiting
  • Advanced Malignant Solid Tumor
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
  • ShangHai, Shanghai, China
  • +1 more
Apr 26, 2021